Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 114

Sort by

Sort Order Select

Journal Articles

Impact of putative cell of origin on CD19+CAR-T outcomes in patients with large B-cell lymphoma

Blood (2025) 146 (Supplement 1): 5500.

https://doi.org/10.1182/blood-2025-5500

Published: 2025

Journal Articles

Evaluation of prognostic factors and survival outcomes in patients with Relapsed/Refractory (R/R) large B-cell lymphomas (LBCLs) treated with epcoritamab

Blood (2025) 146 (Supplement 1): 3739.

https://doi.org/10.1182/blood-2025-3739

Published: 2025

Journal Articles

Outcomes of bispecific T-cell engagers in MM patients with central nervous system (CNS) involvement

Blood (2025) 146 (Supplement 1): 824.

https://doi.org/10.1182/blood-2025-824

Published: 2025

Journal Articles

BCMA CAR T-cell expansion dynamics and toxicity after idecabtagene vicleucel and ciltacabtagene autoleucel for multiple myeloma

Blood (2025) 146 (Supplement 1): 5850.

https://doi.org/10.1182/blood-2025-5850

Published: 2025

Journal Articles

Final results of a multi-center phase 2 trial of isatuximab-lenalidomide in patients with high risk smoldering multiple myeloma (HRSMM)

Blood (2025) 146 (Supplement 1): 5834.

https://doi.org/10.1182/blood-2025-5834

Published: 2025

Journal Articles

Prognostic impact of CXCR4 mutation type on clinical features and outcomes of patients with Waldenström macroglobulinemia

Anath Lionel, Lorenzo Gensini, Sherif Seif, Wenli Dong, Lei Feng, Janelle Sanchez, Hima Bansal, Melody Becnel, Mahmoud Gaballa, Hans Lee, Oren Pasvolsky, Krina Patel, Jing Christine Ye, Keyur Patel, Donna Weber, Robert Orlowski, Sheeba Thomas

Blood (2025) 146 (Supplement 1): 1829.

https://doi.org/10.1182/blood-2025-1829

Published: 2025

Journal Articles

Impact of extranodal sites of lymphoma on clinical outcomes after CD19 CAR T cell therapy

Blood (2025) 146 (Supplement 1): 1931.

https://doi.org/10.1182/blood-2025-1931

Published: 2025

Journal Articles

Real world efficacy of mosunetuzumab in follicular lymphoma patients previously exposed to lenalidomide: A collaborative US bispecifics consortium study

Blood (2025) 146 (Supplement 1): 5384.

https://doi.org/10.1182/blood-2025-5384

Published: 2025

Journal Articles

Sequencing CD20-directed bispecific antibody and CD19-directed CAR T cell therapy in large B cell lymphoma: A multicenter real-world study

Blood (2025) 146 (Supplement 1): 3663.

https://doi.org/10.1182/blood-2025-3663

Published: 2025

Journal Articles

Activity of autologous anti-CD19 chimeric antigen receptor T-cell therapy in CD19-negative large B-cell lymphoma: A cell therapy consortium real world experience

Chen Zhang, Xiaowen Sun, Lei Feng, David Porter, Stephen J. Schuster, Olalekan Oluwole, Veronika Bachanova, Supriya Gupta, Joseph McGuirk, Richard Maziarz, Andy Chen, Sairah Ahmed, Peter Riedell, Anthony Hunter, Paolo Strati

Blood (2025) 146 (Supplement 1): 957.

https://doi.org/10.1182/blood-2025-957

Published: 2025

Journal Articles

Treatment history, not race or duffy-null status, predicts outcomes with teclistamab in Relapsed/Refractory multiple myeloma

Blood (2025) 146 (Supplement 1): 4575.

https://doi.org/10.1182/blood-2025-4575

Published: 2025

Journal Articles

Real-world clinical outcomes with novel agent combination therapies for the frontline treatment of pediatric and adult advanced-stage Hodgkin lymphoma

Blood (2025) 146 (Supplement 1): 1852.

https://doi.org/10.1182/blood-2025-1852

Published: 2025

Journal Articles

Real world experience of anakinra for the treatment of immune effector cell-associated neurotoxicity syndrome in large B-cell lymphoma

Rahul Shah, Xiaowen Sun, Lei Feng, Anath Lionel, Zachary Hunzeker, Sairah Ahmed, Jeremy Ramdial, Michelly Abreu, Karla Ow, Minifrida Santiago, Jaimole Varghese, Sherry Adkins, Misha Hawkins, Sandra Horowitz, Amy Ayers, Partow Kebriaei, Elizabeth Shpall, Sattva Neelapu, Paolo Strati

Blood (2025) 146 (Supplement 1): 6319.

https://doi.org/10.1182/blood-2025-6319

Published: 2025

Journal Articles

Talquetamab for relapsed/refractory multiple myeloma : Real-world outcomes from the US multiple myeloma immunotherapy consortium

Blood (2025) 146 (Supplement 1): 137.

https://doi.org/10.1182/blood-2025-137

Published: 2025

Journal Articles

A phase II investigator-initiated frontline trial of evorpacept (ALX148), lenalidomide and rituximab for high tumor burden indolent b-cell non-Hodgkin lymphoma

Paolo Strati, Lei Feng, Luis Malpica, Ranjit Nair, Ayushi Chauhan, Dai Chihara, Zachary Hunzeker, Laura Murphy, Elizabeth McChesney, Derek Waters, Jason Westin, Sattva Neelapu, Christopher Flowers

Blood (2025) 146 (Supplement 1): 3571.

https://doi.org/10.1182/blood-2025-3571

Published: 2025

Journal Articles

Safety and efficacy of implanted port use for CAR T-cells infusion in large B-cell lymphoma

Zachary Hunzeker, Anath Lionel, Xiaowen Sun, Lei Feng, Sairah Ahmed, Amy Ayers, Michelly Abreu, Jaimole Varghese, Karla Ow, Amelita Marzan, Taylor Cain, Minifrida Santiago, Sreekala Nair, Jeremy Ramdial, Elizabeth Shpall, Sattva Neelapu, Paolo Strati

Blood (2025) 146 (Supplement 1): 2713.

https://doi.org/10.1182/blood-2025-2713

Published: 2025

Journal Articles

Consolidation with loncastuximab tesirine for large B-cell lymphoma patients in partial response after CART: Planned interim futility analysis of a phase II trial

Mark Hamilton, Ajlan Al Zaki, Lei Feng, Zachary Hunzeker, Dai Chihara, Hun Lee, Chitra Hosing, Laura Ebarle, Oluwadare Ajishegiri, Jason Westin, Sairah Ahmed, Sattva Neelapu, Paolo Strati

Blood (2025) 146 (Supplement 1): 5485.

https://doi.org/10.1182/blood-2025-5485

Published: 2025

Journal Articles

Acalabrutinib with Rituximab Is Highly Effective First Line Treatment for Older Patients with Mantle Cell Lymphoma

Blood (2024) 144 (Supplement 1): 3038.

https://doi.org/10.1182/blood-2024-206042

Published: 2024

Journal Articles

Prognostic Significance of TP53 Mutations in Lymphoplasmacytic Lymphoma

Anath Lionel, Sherif Seif, Xiaowen Sun, Lei Feng, Lorenzo Gensini, Bria Gabriel, Lauren S. Lewis, Hima Bansal, Melody R. Becnel, Mahmoud R. Gaballa, Hans C. Lee, Oren Pasvolsky, Krina K. Patel, J Christine Ye, Keyur P. Patel, Donna M. Weber, Robert Z. Orlowski, Sheeba K. Thomas

Blood (2024) 144 (Supplement 1): 3024.

https://doi.org/10.1182/blood-2024-211193

Published: 2024

Journal Articles

Outcomes of Elderly Patients with Relapsed Refractory Multiple Myeloma (RRMM) Treated with Teclistamab: A Multicenter Study from the U.S. Multiple Myeloma Immunotherapy Consortium

Blood (2024) 144 (Supplement 1): 934.

https://doi.org/10.1182/blood-2024-205989

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Impact of putative cell of origin on CD19+CAR-T outcomes in patients with large B-cell lymphoma

Evaluation of prognostic factors and survival outcomes in patients with Relapsed/Refractory (R/R) large B-cell lymphomas (LBCLs) treated with epcoritamab

Outcomes of bispecific T-cell engagers in MM patients with central nervous system (CNS) involvement

BCMA CAR T-cell expansion dynamics and toxicity after idecabtagene vicleucel and ciltacabtagene autoleucel for multiple myeloma

Final results of a multi-center phase 2 trial of isatuximab-lenalidomide in patients with high risk smoldering multiple myeloma (HRSMM)

Prognostic impact of CXCR4 mutation type on clinical features and outcomes of patients with Waldenström macroglobulinemia

Impact of extranodal sites of lymphoma on clinical outcomes after CD19 CAR T cell therapy

Real world efficacy of mosunetuzumab in follicular lymphoma patients previously exposed to lenalidomide: A collaborative US bispecifics consortium study

Sequencing CD20-directed bispecific antibody and CD19-directed CAR T cell therapy in large B cell lymphoma: A multicenter real-world study

Activity of autologous anti-CD19 chimeric antigen receptor T-cell therapy in CD19-negative large B-cell lymphoma: A cell therapy consortium real world experience

Treatment history, not race or duffy-null status, predicts outcomes with teclistamab in Relapsed/Refractory multiple myeloma

Real-world clinical outcomes with novel agent combination therapies for the frontline treatment of pediatric and adult advanced-stage Hodgkin lymphoma

Real world experience of anakinra for the treatment of immune effector cell-associated neurotoxicity syndrome in large B-cell lymphoma

Talquetamab for relapsed/refractory multiple myeloma : Real-world outcomes from the US multiple myeloma immunotherapy consortium

A phase II investigator-initiated frontline trial of evorpacept (ALX148), lenalidomide and rituximab for high tumor burden indolent b-cell non-Hodgkin lymphoma

Safety and efficacy of implanted port use for CAR T-cells infusion in large B-cell lymphoma

Consolidation with loncastuximab tesirine for large B-cell lymphoma patients in partial response after CART: Planned interim futility analysis of a phase II trial

Acalabrutinib with Rituximab Is Highly Effective First Line Treatment for Older Patients with Mantle Cell Lymphoma

Prognostic Significance of TP53 Mutations in Lymphoplasmacytic Lymphoma

Outcomes of Elderly Patients with Relapsed Refractory Multiple Myeloma (RRMM) Treated with Teclistamab: A Multicenter Study from the U.S. Multiple Myeloma Immunotherapy Consortium

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only